Expression And Scoring Of HER2/Neu in Variants of Prostate Adenocarcinoma

Abstract

Objective: To evaluate the immunohistochemical expression and scoring of HER2/neu in different variants of adenocarcinoma of prostate and to compared the association of HER2/neu expression with biological behavior and risk factors of prostate adenocarcinoma. Study Design and Setting: Cross sectional study in which all clinically suspected prostate adenocarcinoma cases received at the laboratory Saddar Karachi during the years 2015 and 2016 were evaluated for morphological features of adenocarcinoma. Methodology: This cross sectional study was carried out using prostate biopsies of clinically suspected prostate adenocarcinoma. The diagnosis of adenocarcinoma was confirmed and histological characterization was done by evaluating the morphological features. The tumors were graded according to the revised 2015 Gleason’s grouping. Immunohistochemical analysis for HER2/neu expression was performed in the most representative tumor block. SPSS version 22 was used for data analysis. Mean frequency and percentages were calculated for quantitative variables, whereas chi-square test and Fisher’s Exact Test were applied for qualitative variables. P-value of < 0.05 was considered as significant. Results: Out of 77 biopsies only one showed moderate HER2/neu expression. Positive HER2/neu was acinar variant. No significant statistical association was observed between expression of HER2/neu and prostate cancer variants. The positive case had age more than 60 years with moderately increased serum PSA levels and was aggressive in nature at the time of diagnosis. Conclusion: It was concluded from the study that HER2/neu was rarely expressed in prostate adenocarcinoma